Profusa Inc. Ordinary Shares PFSA 深 滬
等待開盤 12-16 09:30:00 美东时间
0.1222
-0.030
-19.87%
華盛通- 最 高0.1576
- 今 開0.1571
- 成交量 3042.23万股
- 最 低 0.1181
- 昨 收 0.1525
- 總市值 510.30万
- 52周最高 2.40
- 市盈率 靜 --
- 換手率 72.85%
- 52周最低 0.1159
- 委 比 -96.01%
- 總股本 4175.93万
- 歷史最高 2.40
- 量 比 2.87
- 振 幅 25.90%
- 歷史最低 0.1159
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Profusa Abstract Accepted For LINC 2026; Presentation To Highlight Tissue Oxygen Monitoring Insights In PAD Pilot Study
Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patientsBERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage
12-11 21:37
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 12.1% to $8.18 during Mond...
11-25 05:05
Profusa CEO Says 'Co To Capitalize On The Near-Term European And U.S. Lumee Oxygen Opportunity To Deliver 2026 Potential Revenue Of $500K To $2M And $9M To $13M Potential Revenue In 2027
Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry,
11-20 06:56
STRATA Skin Sciences Rises 25% Pre-Market — Here's Why
STRATA gained on premarket trading after receiving Mexican regulatory approval for its TheraClearX acne treatment system.
10-29 16:43
Why Profusa (PFSA) Stock Soared 36% After Hours?
Profusa shares jumped 36% in after-hours trading after the company completed key manufacturing milestones and outlined plans to start generating revenue from its Lumee systems in early 2026.
10-29 15:30
Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026
Profusa has achieved key manufacturing milestones to support 2026 revenue targets for its Lumee tissue oxygen monitoring systems. The company completed its first sensor production run in a new controlled environment room, with capacity exceeding twice the 2026 requirements. It also engaged a contract manufacturer for Lumee patches/readers and pens, with production capacities exceeding demand. Distribution partnerships and clinical collaborations ...
10-28 12:30
Profusa Unveils Strategic Focus in Investor Update
The latest update is out from Profusa ( ($PFSA) ). On October 20, 2025, Profusa...
10-21 18:34
Profusa To Expand Commercial Footprint For Lumee Oxygen Platform In Europe Under Signed Letter Of Intent With Angiopro GmbH
BERKELEY, Calif, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the
10-15 20:44
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe
Profusa has expanded its commercial footprint in Europe by signing a letter of intent with Angiopro GmbH to establish logistics and commercialization for its Lumee Oxygen platform. Initial target markets include Germany, Benelux countries, Austria, the UK, and Scandinavia. This partnership expands Profusa's distributor coverage to ~35% of the EU population, with ~300,000 annual endovascular procedures. Angiopro's expertise in cardiovascular techn...
10-15 12:30
